Drug Profile
Research programme: peroxisome proliferator-activated receptor gamma agonist - Omeros
Alternative Names: PPAR-gamma agonistLatest Information Update: 28 May 2019
Price :
$50
*
At a glance
- Originator University of Camerino
- Developer Omeros Corporation
- Class
- Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Substance-related disorders
Most Recent Events
- 28 May 2019 No recent reports of development identified for preclinical development in Substance-related disorders in USA
- 10 May 2017 Preclinical development is ongoing in USA
- 16 Mar 2017 Omeros Corporation has patent protection for peroxisome proliferator-activated receptor gamma agonists for additive disorders in USA and ex-US countries